Firms cannot use safety data derived from third-country animal testing to substantiate product safety in accordance with the European Cosmetics Regulation, but such testing does not in itself constitute a violation of the EU’s animal-testing ban. It may be more challenging to compile required safety-assessment reports, but companies don’t necessarily have to choose between the EU and emerging markets such as China.
The European Union’s highest court has decided that cosmetic products marketed in the European Union can contain ingredients tested on animals to meet third-country regulatory requirements, but that data cannot be used to substantiate safety as required by the European Cosmetics Regulation.
Overall, this is good news for industry. Questions have been raised as to whether the EU’s cosmetic animal-testing ban is...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
